LabCorp raises $2.9B in debt for Covance buy; Microsoft holographic glasses could help teach surgeons;

@FierceMedDev: SV Bio changes name to Lifecode, plans rollout of NGS cancer assay. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Celator's delivery platform results in FDA's fast-track designation for its cancer candidate. FierceDrugDelivery article | Follow @VarunSaxena2

@EmilyWFierce: J&J settles the score with over 100 vaginal mesh plaintiffs. More | Follow @EmilyWFierce

> LabCorp ($LH) has raised $2.9 billion in debt to help finance its acquisition of contract research organization Covance ($CVD) for $5.6 billion that was announced in early November. The deal is slated to close during the first quarter. Release

> CareFusion ($CFN) shareholders have approved the $12.2 billion acquisition proposed by Becton, Dickinson and Company ($BDX) in early October with 76% of shares cast for approval. The deal is expected to close during the first half of 2015. Release

> Microsoft ($MSFT) has unveiled its 3D holographic glasses, HoloLens. They are expected to have multiple applications, including surgical training. Story

> AliveCor has received a CE mark for its automated analysis algorithm to detect atrial fibrillation (AF). It analyzes electrocardiogram recordings made by its smartphone plug-in device and automatically notifies the user if AF has been detected. Release

Biotech News

@FierceBiotech: China's Innovent banks $100M to cash in on the biosimilar boom. Report | Follow @FierceBiotech

@JohnCFierce: So Martin Pule, who got his start with Brenner at Baylor on CAR-T ($CELG, $BLUE) went on the Cellectis deal ($ALCLS) is now CSO at Autolous. | Follow @JohnCFierce

@DamianFierce: @IAmBiotech weighs in on Obama's precision medicine plan. More | Follow @DamianFierce

> Kite expands its immuno-oncology brain trust in the CAR-T footrace. Article

> The CAR-T brain war: Scientific trailblazer inspires a $45M biotech startup. Story

Pharma News

@FiercePharma: Report: Livestock research lab prioritizes profits over animal health. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: UK's MHRA expands its ban of Wockhardt's plant in Chikalthana, India to include all APIs. FiercePharmaManufacturing article | Follow @EricPFierce

@CarlyHFierce: Incoming Takeda chief ready to jump on the M&A train with reorg in place. Report | Follow @CarlyHFierce

> Rooting for a French CEO at Sanofi? Take another name off your list of prospects. Story

> Novartis eyes psoriasis dominance with new approvals for Cosentyx. Article

Vaccines News

> After rocky flu season, vaccinemakers may want to follow Novartis' lead. Story

> Disneyland measles outbreak adds fuel to heated anti-vaccination debate. Item

> J&J forms consortia to accelerate Ebola vaccine development, gets €100M boost from IMI. News

> Study: GSK's malaria vaccine may not be effective when used with bed nets. More

> MSF urges GSK, Pfizer to slash pneumococcal vaccine prices. Report

Pharma Manufacturing News

> Manufacturing key to getting more effective flu jabs to market faster. Story

> Gulf Pharmaceutical commits to sterile injectable plant in Ethiopia. Report

> FDA finds more counterfeit Cialis, warns consumers. Article

> U.K. expands Wockhardt ban. More

> Biologics manufacturing helps Lonza to early turnaround. Story

Suggested Articles

The FDA has cleared its first fully disposable duodenoscope, following years of reports of infections being transmitted between patients.

OR-focused AI provider Caresyntax has garnered $45.6 million in new funding and picked up a data analytics firm to broaden its footprint.

A study of Foundation Medicine’s FoundationOne liquid biopsy test found it was able to predict the risk that a person’s breast cancer would return.